Review began 08/13/2021

Review ended 08/25/2021

Published 09/05/2021

© Copyright 2021

Kaur et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

A Rare Case of Gastrointestinal Mucormycosis

Jasneet Kaur¹, Upinder Singh¹, Uma Pradhan², Gulshan Singh², Prem Narayan Agarwal²

1. Department of Pathology, Genomics Laboratory, New Delhi, IND 2. Department of General Surgery, Shree Guru Gobind Singh Tricentenary University, Gurugram, IND

Corresponding author: Uma Pradhan, umapradhan11195@gmail.com

Abstract

Gastrointestinal Mucormycosis (GIM) is a rare life-threatening angio-invasive infection. The classic risk factors include immunosuppression and metabolic derangement. Usually, there are classical risk factors in patients affected by ileocecal mucormycosis. Few case reports have shown the absence of salient clinical presentation of mucormycosis in prolonged hospitalisation. The presence of association of mucormycosis in patients of typhoid infection is rare. Here, we present a case of invasive ileal mucormycosis occurring as a sequel to typhoid infection which lacked the typical risk factors for mucormycosis.

Categories: Pathology, Gastroenterology, General Surgery**Keywords:** gastrointestinal mucormycosis, ileocecal mucormycosis, typhoid infection, melaena, right hemicolectomy

Introduction

Gastrointestinal (GI) mucormycosis is an uncommon, usually opportunistic, life-threatening angio-invasive infection, and accounts for 4 to 7 % of all cases of mucormycosis [1,2]. Traditional risk factors include diabetes, corticosteroid use, immunocompromised state, transplant patients on immunosuppressive therapies and iron overload states with or without deferoxamine therapy, and malnutrition [3]. The association of mucormycosis with typhoid infection is extremely rare [4]. We present here a case of invasive ileal mucormycosis occurring as a sequel to typhoid infection in absence of typical risk factors.

Case Presentation

A 29-year-old male patient with no comorbidities presented with abdominal pain, fever, and yellow discoloration of the eyes for 10 days. On admission, the patient was malnourished with icterus, abdominal distension, and shifting dullness. On examination, BP was 70/40 mm Hg and pulse rate 100/min. Ultrasound abdomen showed hepatosplenomegaly with ascites. He was not on any previous treatment and his covid RT-PCR was negative. Blood culture showed growth of *Salmonella typhimurium*.

The patient was treated with antifungals, ciprofloxacin, and amikacin for typhoid. He developed melaena two weeks later and was not responding to conservative management. Hence, exploratory laparotomy with ileocolic resection and anastomosis was done. Post-op blood culture showed no growth. Gross examination of the right hemicolectomy specimen showed a necrotic polypoid mass protruding into the lumen of the thinned-out terminal ileum with extensive mucosal congestion and ulceration.

Microscopy exhibited transmural necrosis of the ileal wall with acute inflammatory exudate. The intestinal wall, Peyer's patches, and mesenteric lymph nodes showed necrosis (Figure 1). Many aseptate broad based irregular hyphae were seen in the intestinal wall morphologically suggestive of *Mucorales* (Figure 2). Thrombosis of many small and large vessels was also seen occluding the lumen (Figure 1b).

How to cite this article

Kaur J, Singh U, Pradhan U, et al. (September 05, 2021) A Rare Case of Gastrointestinal Mucormycosis. Cureus 13(9): e17748. DOI 10.7759/cureus.17748

FIGURE 1: a) Necrotic tissue with fungal hyphae, H&E x400 b)Thrombosed blood vessel, H&E x200 c) Peyer's patch (star) and thrombosed vessel (arrow), PAS x100 d) Necrotic lymph node, H&E x100

FIGURE 2: a) GMS stain showing fungal hyphae, x400 b) PAS stain showing right-angled branching (arrow), x400 c) Fungal hyphae within necrotic lymph node, PAS x400 d) fungal hyphae invading vessel wall, PAS x400

The patient was discharged in satisfactory condition on posaconazole and antibiotics.

Discussion

Mucormycosis is a fatal infection caused by fungi belonging to the subphylum Mucoromycotina and order Mucorales [5]. GIM (Gastro-intestinal Mucormycosis) accounts for only 7% of all cases, but the mortality rate can be as high as 85%. The most common site of GI mucormycosis is the stomach followed by the colon and ileum [3,6].

Typical risk factors of mucormycosis are diabetes, defects in host phagocytes resulting in the immunocompromised state, corticosteroid use, immunosuppression for organ or stem cell transplantation, and increased levels of serum iron as a result of acidosis or administration of deferoxamine [2,3,7]. GIM has also been reported in the literature in individuals without the typical risk factors of uncontrolled diabetes mellitus or immunosuppression [2,3,8,9,10]. This is called healthcare-associated gastrointestinal mucormycosis occurring in immunocompetent adults who are admitted to the intensive care unit or after prolonged hospitalization and major surgery [11].

GI mucormycosis with concurrent typhoid fever has been very rarely reported in the literature [4]. Pathophysiology of GI mucormycosis in typhoid includes malnutrition, impaired mucosal integrity following *S. typhimurium* enteritis facilitates hyphal invasion into the intestinal wall and impaired phagocytic function of macrophages in typhoid infection further facilitates the growth of fungi [12]. Angioinvasion by the fungi, resulting in thrombosis of vessels and local ischemic necrosis, provides the nidus for hematogenous dissemination [13].

Diagnosis of GIM can often be delayed because of non-specific presentation. The most common symptoms are non-specific abdominal pain and distention associated with nausea and vomiting. Fever and haematochezia can be present. The diagnosis is usually during surgery or endoscopy by biopsy of the suspected area [3]. Successful management requires timely diagnosis, reversal of predisposing risk factors, prompt antifungal therapy, and early surgical debridement [7]. Treatment options include amphotericin B, triazole, Posaconazole [14].

Conclusions

Association of GI mucormycosis with enteric fever is very rare. It assumes importance in developing countries where *Salmonella* infections are very common. The exact mechanism of their association is not well understood but can be attributed to disturbed host immunity in typhoid infections or due to prolonged hospital admission in immunocompetent persons.

Patients not improving on conservative management of typhoid and presenting with melaena warrant exploration. It is important to have a high index of suspicion in these patients so that early identification of such a life-threatening infection can be made.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Kwon-Chung KJ: Taxonomy of fungi causing mucormycosis and entomophthoromycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. *Clin Infect Dis*. 2012, 54:S8-S15. [10.1093/cid/cir864](#)
2. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis*. 2005, 41:634-53. [10.1086/432579](#)
3. Spellberg B: Gastrointestinal mucormycosis: an evolving disease. *Gastroenterol Hepatol*. 2012, 8:140-2.
4. Prabhu RM, Patel R: Mucormycosis and entomophthoromycosis: a review of the clinical manifestations, diagnosis and treatment. *Clin Microbiol Infect*. 2004, 10:S31-47. [10.1111/j.1470-9465.2004.00843.x](#)
5. Hibbett DS, Binder M, Bischoff JF, et al.: A higher-level phylogenetic classification of the Fungi. *Mycol Res*. 2007, 111:509-47. [10.1016/j.mycres.2007.03.004](#)
6. Choi HL, Shin YM, Lee KM, et al.: Bowel infarction due to intestinal mucormycosis in an immunocompetent patient. *J Korean Surg Soc*. 2012, 83:325-9. [10.4174%2Fjkss.2012.83.5.325](#)
7. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Jr, Ibrahim AS: Recent advances in the management of mucormycosis: from bench to bedside. *Clin Infect Dis*. 2009, 48:1743-1751. [10.1086%2F599105](#)
8. Poyuran R, Dharan B S, Sandhyamani S, Narasimhaiah D: Mucormycosis-induced ileocecal perforation: a case report and review of literature. *J Postgrad Med [serial online]*. 2020;2020, 15:48-50. [10.4103%2Fjpgm.JPGM_420_19](#)

9. Sun M, Hou X, Wang X, Chen Ge, Zhao Y: Gastrointestinal mucormycosis of the jejunum in an immunocompetent patient: a case report. *Medicine (Baltimore)*. 2017. 96:1-5. [10.1097%2FMD.00000000000006360](https://doi.org/10.1097%2FMD.00000000000006360)
10. Hu J, Zhou X, Xu C, Ying L, Zheng X: Fatal gastrointestinal mucormycosis in an immunocompetent patient: a case report and review of the literature. *Int J Clin Exp Med*. 2018, 11:4301-4306.
11. Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O: Healthcare-associated mucormycosis. *Clin Infect Dis*. 2012, 54 Suppl 1:S44-54. [10.1093/cid/cir867](https://doi.org/10.1093/cid/cir867)
12. Martinello M, Nelson A, Bignold L, Shaw D: "We are what we eat!" Invasive intestinal mucormycosis: a case report and review of the literature. *Med Mycol Case Rep*. 2012, 52:55. [10.1016%2Fj.mmcr.2012.07.003](https://doi.org/10.1016%2Fj.mmcr.2012.07.003)
13. Petrikos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP: Epidemiology and clinical manifestations of mucormycosis. *Clin Infect Dis*. 2012, 54:S23-34. [10.1093/cid/cir866](https://doi.org/10.1093/cid/cir866)
14. Kontoyiannis DP, Lewis RE: Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. *Infect Dis Clin North Am*. 2006, 20:581-607, vi. [10.1016/j.idc.2006.06.003](https://doi.org/10.1016/j.idc.2006.06.003)